Form 4 for BBOT BridgeBio Oncology Therapeutics, Inc.
Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001193125-26-104379 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-12 | 2026-03-10 | BBOT | Beltran Pedro | CSO | A - Grant | $0.00 | +46.7K | 46.7K | New | $0 |
| D | 2026-03-12 | 2026-03-10 | BBOT | Beltran Pedro | CSO | A - Grant | $0.00 | +210.0K | 210.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-10 | A | A | 46,670 | $0.00 | 46,670 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-03-10 | A | A | 210,000 | $0.00 | 210,000 | D | $10.19 · — to 2036-03-09 | 210,000 Common Stock | (F2) 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |